Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
Linifanib (ABT-869)
Cat No.
CEI-0159
Description
As a structurally novel, receptor tyrosine kinase (RTK) inhibitor, ABT-869 can inhibit PDGFR-beta, KDR, and CSF-1R with IC50 of 2 nM, 4 nM and 7 nM.
Alias
AL-39324
CAS No.
796967-16-3
Molecular Weight
375.405
Purity
>99%
Storage
2 years at -20 centigrade
Synonyms
AL-39324
Targets
KDR, CSF-1R, Flt-1, Flt-3, PDGFR-beta
Molecular Formula
C21H18FN5O
Chemical Name
1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea
Solubility
DMSO 75 mg/mL Water
In vitro
As a structurally novel, receptor tyrosine kinase (RTK) inhibitor, ABT-869 can inhibit PDGFR-beta, KDR, and CSF-1R with IC50 of 2 nM, 4 nM and 7 nM. ABT-869 is competitive with ATP, with Ki values of 3 nM and 120 nM. For cell lines (1) MV-4-11 and MOLM-13 cell lines ABT-869, a multitargeted receptor tyrosine kinase inhibitor, inhibited the phosphorylation of FLT3, STAT5, and ERK, as well as Pim-1 expression in MV-4-11 and MOLM-13 cells with IC50 from 1 nM to 10 nM. ABT-869 inhibited the proliferation of MV-4-11 and MOLM-13 with IC50 of 4 nM and 6 nM through the induction of apoptosis by increasing sub-G(0)/G(1) phase, caspase activation, and PARP cleavage. (2)ABT-869 can also inhibit VEGF-stimulated proliferation of human endothelial cells with IC50 of 0.2 nM. (3) In normal human blood spiked with AML cells, ABT-869 inhibited phosphorylation of FLT3 with IC50 approximately 100 nM. (4) ABT-869 had no significant effect up to 1000 nM on normal hematopoietic progenitor cells, whereas in AML patient samples harboring both FLT3-ITD and wt-FLT3, ABT-869 inhibited colony formation with IC50 of 100 and 1000 nM, respectively.
In vivo
ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models and is also effective in orthotopic breast and glioma models. ABT-869 can reduce tumor size and tumor regression was observed in epidermoid carcinoma and leukemia xenograft models.
Download
Download Datasheet